Literature DB >> 3260311

Estrogen and progesterone receptors in some human myeloma cell lines and murine hybridomas.

L Danel1, C Vincent, F Rousset, B Klein, R Bataille, M Flacher, B G Durie, J P Revillard.   

Abstract

The control of immune responses by sex hormones is well documented but the effect of sex hormones on lymphoid cell subsets is poorly understood. We have investigated the expression of receptors for androgens (AR), estradiol (ER) and progesterone (PR) by human cell lines of the B lymphocyte lineage and by murine myeloma or hybridomas. AR, ER and PR were determined by cytosol and nuclear binding assays. Eleven human lymphoblastoid cell lines obtained by in vitro infection of blood or tonsil B cells with Epstein-Barr Virus (EBV) B95, did not express AR or ER. Similarly, 10 Burkitt's lymphoma cell lines were AR, ER and PR negative with the exception of the pre-B RAJI cells which bear AR. Among 13 cell lines derived from patients with multiple myeloma none expressed AR but five were found to bear ER (20-164 fmol/mg DNA or 5-10 fmol/mg protein). Four of the latter group also bear PR (86-450 fmol/mg DNA). Two mouse hybridomas out of seven tested were ER and PR positive. The MOPC 315 myeloma expressed ER but not PR. The possible functional role of these sex hormone binding sites in cell proliferation and immunoglobulin secretion deserves further investigation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3260311     DOI: 10.1016/0022-4731(88)90124-0

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  10 in total

1.  The effect of testosterone replacement treatment on immunological features of patients with Klinefelter's syndrome.

Authors:  I H Koçar; Z Yesilova; M Ozata; M Turan; A Sengül; I Ozdemir
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

Review 2.  Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection.

Authors:  Zdenek Hel; Elizabeth Stringer; Jiri Mestecky
Journal:  Endocr Rev       Date:  2009-11-10       Impact factor: 19.871

3.  Hormonal contraception and HIV disease progression: a multicountry cohort analysis of the MTCT-Plus Initiative.

Authors:  Elizabeth M Stringer; Mark Giganti; Rosalind J Carter; Wafaa El-Sadr; Elaine J Abrams; Jeffrey Sa Stringer
Journal:  AIDS       Date:  2009-11       Impact factor: 4.177

4.  HIV disease progression by hormonal contraceptive method: secondary analysis of a randomized trial.

Authors:  Elizabeth M Stringer; Jens Levy; Moses Sinkala; Benjamin H Chi; Inutu Matongo; Namwinga Chintu; Jeffrey S A Stringer
Journal:  AIDS       Date:  2009-07-17       Impact factor: 4.177

5.  Estrogen alters thresholds for B cell apoptosis and activation.

Authors:  Christine M Grimaldi; James Cleary; A Selma Dagtas; Dariush Moussai; Betty Diamond
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

6.  Dexamethasone reverses glucocorticoid receptor RNA depression in multi-drug resistant (MDR) myeloma cell lines.

Authors:  L Danel-Moore; M Brönnegard; J A Gustafsson
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

Review 7.  Hormonal contraception and HIV disease progression.

Authors:  Elizabeth Stringer; Erik Antonsen
Journal:  Clin Infect Dis       Date:  2008-10-01       Impact factor: 9.079

8.  Concentration of endogenous estrogens and estrogen metabolites in the NCI-60 human tumor cell lines.

Authors:  Xia Xu; Timothy D Veenstra
Journal:  Genome Med       Date:  2012-04-30       Impact factor: 11.117

Review 9.  The Role of Extracellular Vesicles and PIBF in Embryo-Maternal Immune-Interactions.

Authors:  Julia Szekeres-Bartho; Sandra Šućurović; Biserka Mulac-Jeričević
Journal:  Front Immunol       Date:  2018-12-13       Impact factor: 7.561

Review 10.  Cytokines, Hormones and Cellular Regulatory Mechanisms Favoring Successful Reproduction.

Authors:  Marie-Pierre Piccinni; Raj Raghupathy; Shigeru Saito; Julia Szekeres-Bartho
Journal:  Front Immunol       Date:  2021-07-28       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.